<DOC>
	<DOCNO>NCT02246881</DOCNO>
	<brief_summary>The main objective study compare pharmacokinetics Optivate速 subject 's current FVIII concentrate give bolus dose 50IU/kg . The secondary objective compare first second pharmacokinetic assessment Optivate速 ( recovery subject change batch ) evaluate Optivate速 term clinical tolerance safety .</brief_summary>
	<brief_title>A Study Compare Pharmacokinetics Safety Current Factor VIII Concentrate Optivate速 Haemophilia A .</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Von Willebrand Diseases</mesh_term>
	<mesh_term>Factor VIII</mesh_term>
	<criteria>Previously treat subject severe Haemophilia A ( &lt; 2 % basal FVIII activity ) without inhibitor Factor VIII , least 12 year age , currently receive FVIII concentrate 20 exposure day .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>